Dashboard
Company has a low Debt to Equity ratio (avg) at times
Healthy long term growth as Operating profit has grown by an annual rate 21.02%
The company has declared negative results in Mar'2025 after 7 consecutive positive quarters
With ROE of 9.19%, it has a very expensive valuation with a 2.09 Price to Book Value
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 2,105 Million (Small Cap)
23.00
NA
0.00%
0.09
9.34%
2.06
Total Returns (Price + Dividend) 
Addus HomeCare Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Addus HomeCare Forms Golden Cross, Signaling Potential Bullish Breakout
Addus HomeCare Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has shown positive short-term performance, gaining 1.88% today and 8.08% over the past week, despite a one-year decline. Mixed technical indicators suggest varying market sentiment as the company moves forward.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 98 Schemes (50.21%)
Held by 126 Foreign Institutions (7.89%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 21.78% vs 10.35% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 22.10% vs 21.48% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 9.06% vs 11.31% in Dec 2023
YoY Growth in year ended Dec 2024 is 17.76% vs 35.87% in Dec 2023






